VTVT — vTv Therapeutics Share Price
0.000.00%
Last trade - 00:00- $70.90m
- $36.26m
- $1.02m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.81 | ||
| Price to Tang. Book | 5.81 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 69.72 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -73.12% | ||
| Return on Equity | n/a | ||
| Operating Margin | -2377.58% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.41 | 4 | 2.02 | n/a | 1.02 | n/a | n/a | -18.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Directors
- Robin Abrams CHM (57)
- Deepa Prasad PRE (41)
- Hersh Kozlov DRC (73)
- Richard Nelson DRC (49)
- John Fry IND (59)
- Noel Spiegel IND (73)
- Howard Weiner IND (75)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 2nd, 2015
- Public Since
- July 30th, 2015
- No. of Shareholders
- 47
- No. of Employees
- 23
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 3,189,606
- Address
- 3980 Premier Dr, Suite 310, HIGH POINT, 27265
- Web
- https://vtvtherapeutics.com/
- Phone
- +1 3368410300
- Contact
- Burns Mcclellan
- Auditors
- Ernst & Young LLP
Upcoming Events for VTVT
vTv Therapeutics Inc Annual Shareholders Meeting
vTv Therapeutics Inc Annual Shareholders Meeting
Q2 2025 vTv Therapeutics Inc Earnings Release
Similar to VTVT
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the vTv Therapeutics share price?
As of Today at 06:01 UTC, shares in vTv Therapeutics are trading at $22.23. This share price information is delayed by 15 minutes.
How has the vTv Therapeutics share price performed this year?
Shares in vTv Therapeutics last closed at $22.23 and the price had moved by -13.74% over the past 365 days. In terms of relative price strength the vTv Therapeutics share price has underperformed the S&P500 Index by -20.38% over the past year.
What are the analyst and broker recommendations for vTv Therapeutics?
The overall consensus recommendation for vTv Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the vTv Therapeutics dividend yield?
vTv Therapeutics does not currently pay a dividend.
Does vTv Therapeutics pay a dividend?
vTv Therapeutics does not currently pay a dividend.
When does vTv Therapeutics next pay dividends?
vTv Therapeutics does not currently pay a dividend.
How do I buy vTv Therapeutics shares?
To buy shares in vTv Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of vTv Therapeutics?
As of the previous close price of $22.23, shares in vTv Therapeutics had a market capitalisation of $70.90m.
Where are vTv Therapeutics shares listed?
Here are the trading details for vTv Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: VTVT
What kind of share is vTv Therapeutics?
Based on an overall assessment of its quality, value and momentum vTv Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a vTv Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in vTv Therapeutics is $35.50. That is 59.69% above the last closing price of $22.23.
Analysts covering vTv Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$4.06 for the next financial year.
Find out moreWhat is the trend in the vTv Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like vTv Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +58.21%.
As of the last closing price of $22.23, shares in vTv Therapeutics were trading +37.01% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the vTv Therapeutics PE Ratio?
The vTv Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $22.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of vTv Therapeutics?
vTv Therapeutics' management team is headed by:
- Robin Abrams - CHM
- Deepa Prasad - PRE
- Hersh Kozlov - DRC
- Richard Nelson - DRC
- John Fry - IND
- Noel Spiegel - IND
- Howard Weiner - IND